Follow The Filings

IDYA Ideaya Biosciences Inc.

Health Care, filed as IDEAYA BIOSCIENCES INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 3.5%
  • $19M
  • 1 add

In 2026 Q2 Nathan Fischel added to Ideaya Biosciences.

Who owns this now

Largest portfolio weights among holders, up to 3.5% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Add 3.5%

Who owns IDYA

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 3.5% Add +4.3% 497,240 $19M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by IDYA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All IDYA insider trades
  • $1.6M bought by 1 insider
  • None no sales outside a trading plan
  • $1.4M sold by 2 insiders under 10b5-1 plans
  1. Yujiro S Hata CEO
    Planned sale
    $985K 26,338 shares at $37.41 3.7% of stake
    Traded Oct 6 Filed Oct 8
    ↗
  2. Briseno Andres Ruiz Chief Accounting Officer
    Planned sale
    $382K 9,550 shares at $40.01 27% of stake
    Traded Jul 7 Filed Jul 9
    ↗
  3. Jeffrey Stein Director
    Buy
    $1.6M 50,000 shares at $32.96 +1168% to stake
    Traded Mar 2 Filed Mar 2
    ↗

Also filed in the last 12 months, not counted as buying or selling: 2 stock grants and 2 option exercises.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.07,8.01 Filing Doc
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
8-K 8.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
DEFA14A Filing Doc
DEF 14A Filing Doc
8-K 8.01 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $23.38M $7M $218.71M
Net income -$112.96M -$274.48M -$113.7M
Net margin * -483.0% -3921.1% -52.0%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $532.63M $689.71M $666.73M
Total non-current assets * $116.68M $434.38M $442.6M
Total assets $0.649B $1.12B $1.11B
Total current liabilities $27.1M $46.07M $58.82M
Total non-current liabilities * $1.12M $18.87M $27.58M
Total equity $0.621B $1.06B $1.02B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$115.22M -$247.58M -$71.1M
Cash from investing -$158.46M -$502.56M $69.98M
Cash from financing $362.72M $677.55M $29.78M
Net change in cash $89.04M -$72.59M $28.66M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.